Notes from the Field: Complications of Mumps During a University Outbreak Among Students Who Had Received 2 Doses of Measles-Mumps-Rubella Vaccine — Iowa, July 2015–May 2016
Weekly / April 14, 2017 / 66(14);390–391
Matthew Donahue, MD1; Allison Schneider, MD1; Ugochi Ukegbu, MPH2; Minesh Shah, MD3; Jacob Riley, MS4; Andrew Weigel, MSW4; Lisa James, MSN5; Kathleen Wittich, MD5; Patricia Quinlisk, MD6; Cristina Cardemil, MD7 (View author affiliations)View suggested citation
Views equals page views plus PDF downloads
- pdf icon [PDF]
During July 2015–May 2016, a mumps outbreak occurred at the University of Iowa, which is located in Johnson County (1). A total of 301 cases of mumps were diagnosed among students. To characterize the outbreak, the Johnson County Public Health Department, the Iowa Department of Public Health, and the University of Iowa, with assistance from CDC, conducted an investigation through telephone interviews, medical chart abstractions, and review of immunization records. Among 287 (95%) students with mumps for whom clinical information was available, 20 (7%) patients with complications were identified (16 self-reported and four clinician-diagnosed). The 20 cases included 15 (5%) cases of orchitis, three (1%) of transient hearing loss, two of mastitis, and one of meningitis (one patient had both orchitis and transient hearing loss). All 20 patients had documentation of receipt of at least 2 doses of measles-mumps-rubella vaccine. Because data are limited regarding the presentation and clinical course of mumps complications in persons who have received 2 doses of mumps-containing vaccine, three illustrative cases of complications (orchitis, transient hearing loss, and meningitis) in students with mumps are presented.
On November 17, 2015, a man aged 21 years developed right jaw pain and swelling and received a clinical diagnosis of mumps parotitis; the diagnosis occurred 2 weeks after his roommate had received a mumps diagnosis. By the ninth day after symptom onset, the patient’s parotitis had resolved, but he reported a fever of 101.0°F (38.8°C), and 2 days later, he developed left testicular pain and swelling. Orchitis was diagnosed and he was prescribed nonsteroidal anti-inflammatory drugs and ice packs and had no further follow-up care.
On October 13, 2015, a woman aged 21 years developed progressive right ear pain, cough, and shortness of breath. Two days later, she was treated in a hospital emergency department where she received a diagnosis of right otitis externa and left otitis media, for which she was prescribed amoxicillin and analgesics. Later that day, she went to the University of Iowa Student Health Center because of worsening respiratory symptoms. During that encounter, she was also noted to have right bullous myringitis (purulent inflammation of the tympanic membrane), right parotitis suspected to be mumps, and suspected pneumonia. Azithromycin was prescribed empirically to treat both the bullous myringitis and atypical pulmonary pathogens. A polymerase chain reaction (PCR) test for mumps was performed on a buccal swab specimen and was negative. However, her symptoms and epidemiologic link to the outbreak met the Council of State and Territorial Epidemiologists case definition for a probable case of mumps. One day later, she noticed tinnitus and diminished hearing in her right ear; on day 8, she had audiology testing and was evaluated by an otolaryngologist, at which time she received a diagnosis of moderate right sensorineural hearing loss, attributed to mumps, and conductive hearing loss, attributed to otitis media and myringitis. She was treated for 1 week with prednisone, and all her symptoms resolved by the thirteenth day after onset of parotitis. No repeat audiology testing was performed.
On November 2, 2015, a man aged 21 years developed left facial pain and swelling and tested positive for mumps by PCR on a buccal swab specimen. Twenty-two days after onset of symptoms, he was treated at an emergency department for neck stiffness, fever, and tachycardia. A lumbar puncture was performed, and he was empirically treated for meningitis with acyclovir and ceftriaxone. Volume of cerebrospinal fluid was inadequate for performing PCR testing for mumps, but Gram stain and bacterial culture were negative, and analysis was consistent with viral meningitis (40 lymphocytes/mm3, 60 mg/dL of protein, and 67 mg/dL of glucose). Because the onset of mumps-related meningitis has been described as ranging from 4 days before the onset of parotitis until 3 weeks after (2), the patient’s viral meningitis diagnosis was attributed to mumps. He was discharged with recommendations for symptomatic care, and meningeal symptoms resolved within 1 week.
Complications of mumps have been reported less frequently since licensure and widespread use of mumps-containing vaccines. However, this case series demonstrates that complications still occur, even in persons who have received the recommended 2 doses of measles-mumps-rubella vaccine. In addition, complications can occur at varying times throughout the course of the illness and in the absence of parotitis (2,3). Health officials should remain vigilant for these complications and their relation to mumps, and when mumps is suspected, conduct PCR testing on a buccal swab specimen and serology on a serum specimen (4,5).
Corresponding author: Patricia Quinlisk, email@example.com, 515-281-4941.
1University of Iowa Carver College of Medicine; 2Duke University School of Medicine, Durham, North Carolina; 3Epidemic Intelligence Service, CDC; 4Johnson County Public Health Department, Iowa; 5University of Iowa Student Health & Wellness; 6Iowa Department of Public Health; 7Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, CDC.
- University of Iowa Vice President for Student Life. Mumps health advisory 2015. Iowa City, IA: University of Iowa, Vice President for Student Life; 2015. https://vp.studentlife.uiowa.edu/news/mumps-health-advisory/external icon
- Ritter BS. Mumps meningoencephalitis in children. J Pediatr 1958;52:424–33. CrossRefexternal icon PubMedexternal icon
- McLean DM, Bach RD, Larke RP, McNaughton GA. Mumps meningoencephalitis, Toronto, 1963. Can Med Assoc J 1964;90:458–62. PubMedexternal icon
- Fiebelkorn AP, Barskey AE, Hickman CJ, Bellini WJ. Manual for the surveillance of vaccine-preventable diseases: Mumps [Chapter 9]. Atlanta, GA: US Department of Health and Human Services, CDC; 2012. https://www.cdc.gov/vaccines/pubs/surv-manual/chpt09-mumps.html
- CDC. Mumps: general laboratory testing. Atlanta, GA: US Department of Health and Human Services, CDC; 2017. https://www.cdc.gov/mumps/lab/qa-lab-test-infect.html
Suggested citation for this article: Donahue M, Schneider A, Ukegbu U, et al. Notes from the Field: Complications of Mumps During a University Outbreak Among Students Who Had Received 2 Doses of Measles-Mumps-Rubella Vaccine — Iowa, July 2015–May 2016. MMWR Morb Mortal Wkly Rep 2017;66:390–391. DOI: http://dx.doi.org/10.15585/mmwr.mm6614a4external icon.
MMWR and Morbidity and Mortality Weekly Report are service marks of the U.S. Department of Health and Human Services.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.
All HTML versions of MMWR articles are generated from final proofs through an automated process. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (https://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables.
Questions or messages regarding errors in formatting should be addressed to firstname.lastname@example.org.